Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04817007 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
A Phase 1 study of Myelofibrosis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
- 20
- Study locations
NCT04817007: Active Phase 1 study of Myelofibrosis, sponsored by Bristol-Myers Squibb.
NCT04817007 is a Phase 1 study of Myelofibrosis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 216 participants, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04817007, a Phase 1 study of Myelofibrosis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG BMS-986158
- DRUG Fedratinib
Study Locations (20)
Other
- Local Institution - 0030 - Brest
- Local Institution - 0008 - Marseille
- Local Institution - 0027 - Nice
- Local Institution - 0011 - Paris
- Local Institution - 0010 - Villejuif
New South Wales
- Local Institution - 0036 - Blacktown
- Local Institution - 0032 - Wollongong
Victoria
- Local Institution - 0007 - East Melbourne
- Local Institution - 0006 - Heidelberg
Western Australia
- Local Institution - 0041 - Nedlands
- Local Institution - 0015 - West Perth
California
- Local Institution - 0069 - Newport Beach
Florida
- Local Institution - 0090 - Lake Mary
Louisiana
- Local Institution - 0043 - New Orleans
Massachusetts
- Local Institution - 0038 - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
What the registry record for NCT04817007 still lists
NCT04817007 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 3 interventions - of which Ruxolitinib is the first listed.
NCT04817007 names 20 study sites across 13 states, led by Other, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT04817007 about?
NCT04817007 is a clinical study titled "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)". The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-98615...
What is the current status of trial NCT04817007?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2021-03-22. Estimated completion is 2026-05-31.
What conditions does trial NCT04817007 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04817007?
The interventions under investigation include: Ruxolitinib (DRUG), BMS-986158 (DRUG), Fedratinib (DRUG).
Who is sponsoring clinical trial NCT04817007?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04817007 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04817007's enrollment target sits among peer trials
216 11th of 61 higher than 50 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI